ArticleNeuro-oncology2012

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Cécile Colavolpe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.